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httpcense.Abstract Background: CD4+CD25+FoxP3+ circulating regulatory T cells (Treg) play a funda-
mental role in the control of immune responses by down-regulating the function of effector CD4+
or CD8+ T cells. Active suppression by Treg might be important in controlling immune responses
against Mycobacterium tuberculosis (Mtb). This study was conducted to evaluate the cellular
immune response to Mtb, by evaluation of Treg cells in peripheral blood mononuclear cells
(PBMCs) from patients with active pulmonary tuberculosis (PTB), patients with tuberculous pleu-
risy (TP) and healthy positive PPD persons as control, then evaluation after 6 months of anti-TB
therapy, also evaluation of Treg cells in pleural ﬂuid mononuclear cells (PFMCs) from patients with
tuberculous pleurisy (TP). We compared the frequency of CD4+CD25+FoxP3+ circulating reg-
ulatory T cells (Treg) in 20 patients with active pulmonary TB (PTB), 15 tuberculous pleurisy (TP)
and 20 control latent tuberculosis.
Results: Treg frequencies in peripheral blood were signiﬁcantly higher in patients with PTB and
TP than in the control group (p< 0.001). Treg frequencies were signiﬁcantly higher in pleural effu-
sions than in peripheral blood in the same group (p< 0.001). Treg frequencies in peripheral blood
were signiﬁcantly decreased after 6 months of anti-TB treatment (p< 0.001).
Objectives: Immune regulatory mechanisms may limit the immunopathologic condition of
infection with M. tuberculosis and suppress cellular immune responses in the host. We investigated
the CD4+CD25+FoxP3+ circulating regulatory T cells (Treg) in patients with pulmonary
tuberculosis, tuberculous pleurisy and latent TB, and the frequencies of CD4+CD25+FoxP3+
T-cells after anti-TB therapy.4195910.
.com (E.O. Arram).
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168 E.O. Arram et al.Conclusion: MTB infection is associated with an increase in the frequency of
CD4+CD25+FoxP3+ Treg in the blood of PTB and TP, in the pleural ﬂuid of TP, decrease in
the frequency after anti-TB therapy.
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Tuberculosis (TB) is one of the leading causes of morbidity
and mortality worldwide [1]. The most severe burden of TB
disease is happening in developing countries [2].
T cells-mediated immunity plays a central role in host
resistance to TB infection that consists mainly of MTB speciﬁc
Th1-type IFNc secreting CD4 that recruit monocytes, granu-
locytes and effective T cells migrating to disease sites to limit
bacterial reproduction and dissemination [3]. Although this
response aids to limit both bacterial replication and dissemina-
tion but it may cause signiﬁcant immunopathology [4,5].
The immune system has regulatory mechanisms for
suppressing the effector response to persistent antigens, and
these are assumed to limit immune-mediated tissue pathology
[6]. CD4 Regulatory T cells (Treg) play an important role in
immune regulation to prevent autoimmunity diseases and to
control the immune responses by down-regulating the function
of effector CD4+ or CD8+ T cells [7,8].
Several subsets of regulatory T cells have been identiﬁed
such as IL-10 (Tr1) or TGF-b secreting regulatory T cells
(TH3) and CD4+CD25+FoxP3+ regulatory T cells [9,10].
The latter, initially deﬁned by the expression of CD25, the a-
chain of the IL-2 receptor, also share common markers with
conventional, activated CD4+ T lymphocytes [11]. The
forkhead/winged helix transcription factor FoxP3 appears
fundamental for the development and function of these sup-
pressive cells and their most speciﬁc molecular marker [12].
It has been well documented that CD4+CD25+FoxP3+
Treg contributes to cancer-induced immunosuppression [13].
In addition, it has been demonstrated that these immunu-
nosuppressive cells play a role in chronic infection by micro-
bial pathogens such as hepatitis B virus, HIV, leishmania,
Helicobacter pylori etc. [26–28].
Among the different clinical manifestations of tuberculosis,
pulmonary tuberculosis (PTB) and tuberculous pleurisy (TP)
are frequent presentations. PTB has been more extensively
studied in terms of host defense and immunopathogenesis
since this is the most common presentation of Mycobacterium
tuberculosis. TP is also of particular interest. Host defense
against MTB in TP involves inﬁltration of the pleural ﬂuid
by peripheral blood mononuclear cells (PBMCs) including
CD4+ T cells. Thus, TP represents a suitable model to study
MTB-speciﬁc immune response at the site of infection [14].
Little is known about the proﬁle of Treg cells in patients
with TB from the endemic region of Egypt.
Methods
20 patients with Acid fast bacilli (AFB) smear-positive patients
(PTB), 15 Patients with TP, and 20 control subjects with latent
tuberclosis were enrolled in this study. Pulmonary tuberculosis
diagnosis was based on clinical picture, chest X ray examina-
tion and use of Ziehl-Neelsen stain.The severity of tuberculosis based on the radiological
grades of TB was based on the extent of pulmonary involve-
ment and cavitation on chest X ray [15].
The healthy control was positive for puriﬁed protein
derivative, showed no radiographic abnormalities.
Exclusion criteria
Patients were excluded if they had any of the following condi-
tions: concurrent immune-related diseases (including a positive
test for human immunodeﬁciency virus), severe heart, liver,
kidney or brain disease, cancer, nontuberculosis mycobacterial
infection, as assessed by sputum culture, or multi-drug-resis-
tant TB, as diagnosed by drug susceptibility testing.
Sample preparation
Peripheral blood mononuclear cells (PBMCs) were isolated
from Ethylenediamine tetraacetic acid (EDTA) whole blood
using Ficoll density gradient centrifugation. Pleural ﬂuid
mononuclear cells (PFMCs) were obtained by centrifuging
50–200 mL pleural ﬂuid at 300g for 5 min. PBMCs and
PFMCs were washed twice and subjected to further analyses.
Determination of the amount of CD4+CD25+FoxP3+
1 mL of phosphate buffer saline (PBS) was added to 200 ll of
each PBMCs suspension (cell count 2 · 106 cells/ml) and
washed by centrifugation at 2000 rpm for 5 min at room
temperature, discard the supernatant ﬂuid; add 10 ll of
FITC-labeled monoclonal anti-CD4 antibodies (BioLegend,
San Diego, CA, USA) and then left for 30 min at room tem-
perature in the dark and washed twice. After supernatant
was discarded, 10 ll of phycoerythrin (PE)-labeled monoclonal
anti-CD25 antibodies was added to each tube then left for
30 min at room temperature in the dark and washed twice.
For intracellular Foxp3 staining the process of cell perme-
abilization was performed as indicated in the manufacturer’s
manual (Becton Dickinson). We alternately added working
solutions of standard buffers to every test tube: Human FoxP3
Buffer A and Human FoxP3 Buffer C from the set BD Pharm-
ingen. 10 ll of PE-conjugated anti-FOXP3 mAb was added,
and incubation was performed in dark for 30 min at room tem-
perature. Then the cells were twice washed with PBS.
Flow cytometric analysis was performed by FACS calibur
ﬂow cytometer. Lymphocytes were gated according to forward
and size scatter, and 10,000 events were analyzed. The data
were also analyzed by Cell Quest software.
Results
This study was conducted on 20 cases with the diagnosis of
pulmonary tuberculosis, 15 cases with the diagnosis of
CD4+CD25+FoxP3+ circulating Treg cells in tuberculous patients 169tuberculous pleurisy and 20 healthy positive PPD control
cases, both patients and control were cross matched for age
and sex.
Treg percent in peripheral blood of PTB cases was
20.13 ± 6.93 while in TP cases was 19.30 ± 5.06 and it was
6.60 ± 1.91 in control cases, there was a statistically signiﬁcant
difference between the three groups see (Figs. 1 and 2).
Statistically signiﬁcant difference was observed between
CD4CD25 fox P3 Treg percent in PMBCs of TP patients
(19.30 ± 5.06) vs 27.61 ± 6.43 in PFMCs of TP, P va-
lue < 0.001 see (Tables 1–3 and 5).
Table 4 and Fig. 3 show CD4CD25 fox P3 Treg percent in
PBMC of PTB increase with radiological severity, it was
14.47 ± 1.77 in mild stage, 20.22 ± 3.92 in moderate advanced
stage, while in severe advanced stage it was 33.00 ± 4.05 with a
statistically signiﬁcant difference (P< 0.001).Discussion
The estimated worldwide incidence of TB and MDR-TB con-
tinues to increase. Despite the success of medical therapyControl      
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Figure 1 Representative ﬂow cytometric analysis of CD4 and CD2
positive PPD control subject and a patient with PTB.
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Figure 2 Signiﬁcant positive correlation between CD4CD25 fox P3
blood of the same group (r= 0.871, P< 0.001).alone, resistance to drugs and complications of the disease still
present a challenge [16].
The adaptive immunity induced byM. tuberculosis predom-
inantly depends on CD4+ T cells and is critical for the control
of the infection [3].
Active TB is characterized by a profound and prolonged
suppression ofM. tuberculosis (MTB)-speciﬁc T cell responses,
as evidenced by decreased production of the cytokines interleu-
kin (IL)-2 and interferon (IFN)-c Overproduction of immuno-
suppressive cytokines [IL-10 and transforming growth factor
(TGF)-b] by mononuclear phagocytes has been implicated in
decreased T cell function during TB [24].
CD4+CD25+FoxP3+ Treg cells are considered critical
for suppressing immune responses to self-antigens and
preventing autoimmunity and for regulating immunity to for-
eign antigens, especially those derived from pathogens that
establish persistent infections [10].
Treg cells were found to prevent eradication of tubercle
bacilli by suppressing an otherwise efﬁcient CD4+ T-cell
response. To investigate Treg cells, we used the markers
CD4+ and high levels of cell-surface CD25 expression and
intracellular FoxP3 expression [17].                            PTB 
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Table 2 CD4CD25 fox P3 Treg percent in peripheral blood in patients with pulmonary tuberculosis (PTB), with tuberculous pleurisy
(TP) and in healthy control cases.
PTB (n= 20) TP (n= 15) Healthy control (n= 20) P value
CD4CD25 fox P3 Treg 20.13 ± 6.93 19.30 ± 5.06 6.60 ± 1.91 <0.001
Data were presented as mean ± SD, P< 0.05 signiﬁcance.
Table 3 Comparison between CD4+CD25+FoxP3+ Treg percent in PBMCs of TP and PFMCs of the same group.
PBMCs of TP (n= 15) PFMCs of TP (n= 15) P value
CD4CD25 fox P3 Treg 19.30 ± 5.06 27.61 ± 6.43 <0.001
Data were presented as mean ± SD, P< 0.05 signiﬁcance.
Table 4 Relation between CD4CD25 fox P3 Treg percent in PBMCs of PTB and radiological severity.
Mild (n= 7) Moderate advanced (n= 10) Severe advanced (n= 3) P value
CD4CD25 fox P3 Treg 14.47 ± 1.77 20.22 ± 3.92 33.00 ± 4.05 <0.001
Table 1 The demographic data of the case control study population as regard age and sex.
PTB (n= 20) TP (n= 15) Healthy control (n= 20) P value
Age (years) 40.95 ± 10.63 44.60 ± 9.54 36.65 ± 12.01 0.120
Sex
Female 7 (35%) 6 (40%) 9 (45%) 0.812
Male 13 (65%) 9 (60%) 11 (55%)
170 E.O. Arram et al.It is therefore rational to determine whether
CD4+CD25+ Treg lymphocytes that expand during the dis-
ease are able to modulate the function of conventional effector
CD4+ T cells. To address this question,
CD4+CD25+FoxP3+ Treg cells from PBMCs were evalu-
ated in patients with pulmonary tuberculosis and tuberculous
pleurisy and Treg cells from PFMCs in tuberculous pleurisy.
Expansion of CD4+CD25+FoxP3+ T cells at the time of
diagnosis of TB in the current study may, similarly, suggest a
regulatory role for this cell type.
As the host response increase to counteract the intense
inﬂammatory response at sites of active MTB infection, such
as the lung,the same immunoregulatory properties may then,
paradoxi-cally, depress anti-MTB T cell responses necessary
to control infection.
CD4+CD25+FoxP3+ Treg cells were signiﬁcantly in-
creased in peripheral blood of patients with active pulmonary
TB, which is in agreement with the report by Guyot-Revol
et al. [4]. Another report by Ribeiro-Rodrigues et al. [23] also
showed an increase in Treg frequency in PBMCs of PTB
patients.
Also, CD4+CD25+FoxP3+ Treg cells were signiﬁcantly
increased compared with those with latent TB infection.
Several studies also found that CD4+ CD25 high FoxP3
cells were signiﬁcantly higher in PBMCs of patients with active
pulmonary TB as compared with those with latent TB infec-
tion and healthy controls, with no difference between those
with latent infection and healthy controls [18,19].One possible mechanism for Treg cells suppressing anti-M.
tuberculosis immunity is that CD4+CD25+FoxP3+ regula-
tory T cells produce the cytokine TGF-b and/or IL-10, which
depresses interferon-gamma (IFN-c) production [20].
This study showed that CD4+CD25+FoxP3+ cells were
signiﬁcantly decreased in peripheral blood of patients with
PTB and TP after 6 months of anti-TB therapy, similar results
have been found by Wu et al. [19], they found that
CD4+CD25+FoxP3+ cells were signiﬁcantly decreased in
peripheral blood at 6-months postoperatively as compared
with preoperatively in pulmonary resection in the treatment
of cavity multidrug resistant tuberculosis, while Ribeiro-
Rodrigues et al. [23] reported that the frequencies of
CD4+CD25+FoxP3+ T cells were increased in blood from
TB patients compared to healthy puriﬁed protein derivative
(PPD)-positive controls (with a history of prior TB exposure),
and remained elevated at the completion of therapy
(6 months).
In this study the reason remains unclear, particularly as
previous ﬁndings indicate that levels of TGF-b and IL-10 nor-
malize even before the end of treatment [24]. One possible
explanation is that MTB-responsive CD4 T cells present in
the blood at the time of diagnosis of TB may be recruited to
the lung once anti-TB therapy is initiated, to counteract the in-
tense local inﬂammatory response in situ and to prevent the
ensuing tissue damage. These cells then may recirculate back
to the blood as the inﬂammation at the site of infection
decreases.
Table 5 Comparison between CD4CD25 fox P3 Treg in PBMCs in PTB and TP patients before treatment and after 6 months of
receiving anti-TB therapy.
Before treatment After anti-TB therapy P value
CD4CD25 fox P3 Treg 19.77 ± 6.13 7.57 ± 4.43 <0.001
Data were presented as mean ± SD, P< 0.05 signiﬁcance.
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Figure 3 CD4+CD25+FoxP3+ T cells percent in relation to
radiological severity.
CD4+CD25+FoxP3+ circulating Treg cells in tuberculous patients 171The Treg has been implicated in infectious diseases, partic-
ularly in chronic or persistent infections [10,21]. Discordant re-
sults were found in terms of Treg expansion during active TB
disease, some authors reporting an increase of CD4+CD25+
FoxP3+ T cells, whereas others reported the absence of mod-
ulation of this T cell subset [4,22].
The mechanism of CD4+CD25+ Treg suppression re-
mains a matter of controversy [11].
Tuberculous pleurisy (TP) is a suitable model to study the
local immune response because the immunological reactivity
against MTB is compartmentalized in the pleural space. We
therefore sought to investigate the relationship between Treg
and MTB-speciﬁc immunity in the pleural ﬂuid mononuclear
cells from TP patients. The percentage of CD4+CD25+
FoxP3+ Treg in the PFMCs from TP patients was signiﬁ-
cantly higher compared to those in the blood of TP patients
(p< 0.001). Similar results have been shown by others [22,25].
Treg increases in the peripheral blood of PTB patients com-
pared to healthy donors. These ﬁndings are in agreement with
other reports suggesting the involvement of CD4+CD25+
FoxP3+ T cell in human TB [4].
In summary, MTB infection is associated with an increase
in the frequency of CD4+CD25+FoxP3+ Treg in the blood
of PTB and TP, in the pleural ﬂuid of TP, decrease in the fre-
quency after anti-TB therapy.
Further studies should be directed at identifying the medi-
ators and mechanisms involved in the immunoregulatory
properties of CD4+CD25+FoxP3+ T cells as cytokines in-
volved during the course of human MTB infection.
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